adjust dilut earn per share ep defin report
relat cost discontinu oper certain signific
ttr amyloid cardiomyopathi kol call highlight like broad use tafamidi
popul given standout data separ updat model post
result also rais tafamidi forecast target price rais
given higher estim
last week european societi cardiolog congress present strong
data phase attr-act trial tafamidi transthyretin famili amyloidot
cardiomyopathi ttr-fac result also concurr report nejm along
gener favor editori opinion
ttr-fac caus transthyretin amyloid fibril deposit heart contribut
ventricular wall thicken decreas cardiac function ultim lead heart
failur hf preserv eject fraction tafamidi oral transthyretin stabil
prevent tetram dissoci amyloidogenesi receiv orphan drug
track breakthrough therapi design ttr-fac
kol key investig attr-act sever hundr patient ttr-
fac care say volum grow exponenti due awar
advanc diagnosi took year see first peopl center
seen patient last current treat patient
center present hereditari attrm genotyp vs
attrwt genotyp time expect patient present shift attrwt
hereditari attrm becom diminish portion
tradit patient ttr-fac year life-expect larg due late
diagnosi howev kol seen diagnosi referr landscap begin chang
year ago hf patient preserv eject fraction intoler standard
medic would diagnos via mri biopsi show heart-wal thicken
suggest amyloidosi nuclear imag modal pyp-scanning/scintigraphi
becom standard perform easili clinician offic without
biopsi ad diagnos tip iceberg current
patient detect expect diagnosi rate continu grow extrem
rapidli base ttr-fac hf statist estim rang hattr
patient wtattr patient us estim within
hattr-fac popul mix phenotyp
variant experi pure fac phenotyp manifest
believ diagnos pool fac patient pois expand given perfect storm
heighten awar improv diagnosi first markedli effect
treatment tafamidi tafamidi pharmacolog treatment abl
show reduct mortal morbid all-caus ttr-fac consult
believ mortal hospit reduct greater earlier-diagnos class i-ii
subgroup possibl rang believ singl trial
pleas see page report import disclosur
outperform rate stock key averag bottom-lin growth
improv innovation/new product flow solid dividend yield
compel valuat share appear under-valued sotp basi
xtandi eu approv non-metastat
tafamidi regulatori file ttr
cardiomyopathi
ibranc pallet data neoadjuv
breast cancer patent extens
decis consum busi futur
everi earli stage product
launch achiev
ibranc palbociclib adopt even
brisk expect
pipelin achiev greater expect
accret potenti break-up
compani lead greater valuat
pfizer inc global biopharmaceut compani divers portfolio pharma product
cover area cardiovascular anti-infect anti-inflammatori oncolog
metabol diseas other also strong vaccin portfolio consum product
segment array brand product
suffici fda approv ad tafamidi first-in-class drug
payer like support note indic spa
drug ttr-fac beyond strength statist support
singl trial submiss line publish fda guidanc without extra
flexibl breakthrough statu
also forese broad use across attrm attrwt genotyp non-
discriminatori use across sever ttr-fac nyha class i-iii attr-
act trial data came scrutini combin outcom primari
endpoint appear better attrwt patient attrm
patient although magnitud benefit given
sampl size wtattr addit combin outcom nyha
class ii patient less sick popul appear better
class patient howev kol reiter attr-act
data show mortal benefit subgroup trial
power determin differ across subgroup includ low
dose subgroup given small patient number comment
would challeng deni tafamidi treatment wtattr class
patient still like realiz least modest benefit follow-up
discuss kol state would like prescrib
dose less-stabl variant patient may improv surrog
kol consider experi mutat
commonli link ttr-fac even though segment patient
develop peripher neuropathi prior ttr-fac note instanc
rare believ patient prime candid tafamidi upon
approv kol note treat hattr patient far less
frequent total fac patient commonli present
mostli polyneuropathi addit cardiomyopathi treatment
option extrem limit subgroup ttr silenc
recent approv onpattro akca/ion tegsedi current fda
review pdufa would appropri popul
kol current believ would use equal although adam
choic may well almost entir dictat insur
coverag note factor onpattro vs tegsedi decis
could safeti profil two drug well eas administr
onpattro iv vs tegsedi weekli sc administr
kol favor develop next-gener ttr stabil
silenc help hattr-fac mix phenotyp subgroup
also move overal fac field includ wtattr forward think
trial would enrol quickli provid includ pbo arm
howev caution special attent made specif
aspect trial design suffici trial length month allow
cardiac benefit heart remodel function revers
design trial push field includ tafamidi
new soc exploratori drug combin arm kol hypothes
clinic effect seen silenc month neuropathi
symptom potenti ttr intermedi oligom certain
variant patholog nerv tissu contrast ttr fibril
take longer form deposit patholog cv tissu
therefor silenc fac trial least month see clinic
kol believ key care ttr-fac patient lie earli diagnosi
treatment neither ttr stabil silenc remov amyloid
alreadi deposit heart opinion earli treatment prevent
ttr-fac progress hypothesi support outcom
early-stag tafamidis-tr patient attr-act trial ttr-fac
popul kol believ patient start present
clinic syndrom hf would suitabl drug treatment may even
consid late note exampl al amyloidosi earli
diagnosi treatment patient mayo stage low-
biomark receiv stem cell transplant lead markedli improv
outcom surviv rate versu patient mayo stage
iv al amyloid inelig transplant mortal
unfortun patient present heart failur still wait
month year proper ttr-fac diagnosi kol view
still long ask earli ttr-fac could detect
kol conjectur could see untreat surviv better
field shift toward early-diagnosi current involv
activ ascertain program pyp-scan at-risk individu
order identifi ttr-fac patient earlier said believ
unlik at-risk patient carri mutat start
drug present phenotyp would favor treat patient
posit pyp-scan even asymptomat higher chanc
develop activ progress diseas
result updat model ep estim
rais vs guidanc forecast
rais year
total sale increas
tafamidi sale
increas
compani data cowen compani
compani data cowen compani
innov eu lc ex develop emerg develop emerg eu lc ex develop emerg total ex us eu lc ex develop emerg cowen
compani data cowen compani
compani data cowen compani
compani data cowen compani
compani data cowen compani
compani data cowen compani
compani data cowen compani
compani data cowen compani
compani data cowen compani
compani data cowen compani
compani data cowen compani
compani data cowen compani
compani data cowen compani
innov box warn remov patent expir could get pedi exclusivitychampix/chantix eu lc ex fx champix/chantix warn relax patent expir septemb develop emerg smoke cessat pressur suicid concerns/label revenu record line begin innov exp appli pedi exclus lyrica cr offer conveni advantagelyrica develop emerg monotx central neuropath pain due spinal injuri post op pain cr qd bid w/lli phase chronic low back cancer oa pain data filingtot innov eu lc ex fx enbrel launch lifmior enbrel dual brand yet launchedenbrel develop emerg total ex us arthriti right foreign mkt ex /canada patent expir eu xeljanz ra ucxeljanz eu lc ex fx xeljanz ra ucxeljanz develop emerg oral topic inhibitor mild/moder atop dermat pedi/adult approv file eu via anacor acq close estim peak sale inhibitor atop dermat phase breakthrough rheumatoid arthriti phase ii ibd phase rheumatoid arthriti phase rheumatoid arthriti alopecia areata ulcer coliti crohn diseas phase psoriasi alopecia areata ulcer coliti crohn diseas phase blocker inflammatori disord phase blocker ulcer coliti biolog phase iitot innov cowen
compani data cowen compani
innov sulfat er/naltrexon co-formul launch recal supplement approv approv re-launch mu-typ opiod receptor agonist sever pain approv pain innov eu lc ex fx genotropin develop emerg hormon children diabet inhibitor mrk/pfe split approv eu indic long bone fractur spinal growth hormon antagonist acromegali via coa-carboxylas inhibitor non-alcohol steatohepat nash fast premarin osteoporosis/menopaus symptom market eu market author khk inhibitor nash total innov drugsbenefix eu lc ex fx benefix develop emerg competit pressur cowen
compani data cowen compani
innov drug cont drefacto/xyntha eu lc ex fx refacto/xyntha develop emerg xyntha albumin free competit pressuresviagra essenti health exp gener launchedrapamun eu lc ex fx rapamun exp eu posit chmp june sporad lymphangioleiomyomatosisrapamun develop emerg kidney transplant reject oral tab supportsvyndaqel tafamidi dissoci inhib polyneuropathi approv eu file cardiomyopathi achiev endpt piiifidanacogen therapy/coagul factor ix hemophilia biolog breakthru/orphan /eu phase overact bladder eu somatrogon agonist gh defici biolog orphan statu us/eu piii adult piii pedi rivipansel antag vaso-occlus crisi assoc sickl cell diseas fast track orphan /eu gtx hemophilia biolog fast track/orphan us/eu phase iixiaflexnmnmpf ex-u right agreement end alfa gaucher diseas approv protalixoth gip innov innov innov cowen
compani data cowen compani
innov tyrosin kinas inhibitor approv adjuv rcc patent expir februari eu lc ex fx sutent expir juli file adjuv rccsutent develop emerg gleevec-resist gist rcc gu gi ibranc line advanc breast cancer approv label bc set inibr eu lc ex fx trial base paloma develop emerg inhibitorxalkori tx advanc nsclc small percent patient lung cancer patient xalkori eu lc ex fx xalkori develop emerg oral c-met inhibitor competit clipsinlyta lung thyroid hepat melanoma glioblastoma liver combo keytruda combo xalkori rccinlyta eu lc ex fx inlyta develop emerg vegf tyrosin kinas inhibitor pdufa us file eu brca-mut breast cancer revenu gross profit split astella record line start inhib merck kgaa market merkel cell line bladder nsclc ovarian renal gastric urotheli scchn cml io asset abl/src kinas inhibitor approv line calicheamycin conjug r/r approv eu inhib nsclc pdufa phase penetr blood brain smoothen antagonist aml file orphan statu pan-her inhibitor egfr nsclc file previous tx advanc studi market renal cell cancer mantl cell fgn mkt pursu pat exp ex total innov cowen
compani data cowen compani
innov recommend adult post capita dataprevnar eu lc ex fx prevnar reimburs gain country-by-countri basisprevnar develop await reimbursementprevnar emerg valent pneumococc conjug enceph market countri acquir diseas approv eu adolesc young difficil coliti vaccin prophylact fast track phase market acquir staphylococcu aureu vaccin prophylact phase ii fast non-invas pneumococc infect phase non-invas pneumococc infect phase iimeningitecnmnmmeningococc group vaccin spain biotech acquir innov vaccin innov productsadvil consum innov innov innov pfizer total sale cowen
compani data cowen compani
essenti gener launch eu lc ex fx lipitor basic patent expir pedi extensionlipitor develop basic patent expir emerg patent expir juli chinalipitor cholesterol reduct market growth anticipatednorvasc eu lc ex fx norvasc develop emerg competit erod franchis temper emerg rowcardura eu lc ex fx cardura develop emerg competit erod franchis temper emerg rowcaduet eu lc ex fx caduet develop emerg combin gener launchedfragmin lmw heparin ucad hip abdom surg pat exp fragmin eu lc ex fx fragmin develop emerg hypertens post atrial arrhythmia gener launch competit pressur litig essenti cowen
compani data cowen compani
essenti expir eu lc ex fx zyvox expir -develop emerg infectionsvfend settlement gener enter market eu lc ex fx vfend expir develop emerg market new form patent exp eu lc ex fx zosyn exp develop emerg antibioticzithromax patent expir eu lc ex fx zithromax develop patent expir emerg spectrum antibiot declinetygacil expir eu lc ex fx tygacil expir develop emerg seriou gram anerob atyp resist infectionsmerrem expir eu lc ex fx merrem expir merrem develop canada australia new zealandmerrem emerg antibiot record incom account hurdl avi beta lactamas inhibitor/cephalosporin seriou infect approv june ciai/cuti right record incom account hurdl antifung esophag lactamas inhib /cephalosporin mrsa phase ii foreign patent macrolid antibiot declin sale due extend spectrum cephalosporin pneumonia/skin infecti launch file moderate/sever essenti cowen
compani data cowen compani
essenti eu lc ex fx lyrica gad patent expir pain patent expir competit pressurestot launch eu lc ex fx pristiq develop emerg depress market grow modestli vasomotor symptom indic withdrawnzoloft competit pressureszoloft eu lc ex fx zoloft expir februari develop japan possibl zoloft emerg expir eu lc ex fx geodon develop emerg adjunct bipolar depressioneffexor gener competit post eu lc ex fx effexor expir major marketseffexor develop file withdrawneffexor emerg depress market grow modestlyaricept eu lc ex fx aricept sale licens agreementaricept develop emerg gener competit xr form xr patent anxieti drug off-pat sold right eletriptan patent expir newer anti-epilepsi intern growth help off-set essenti cowen
compani data cowen compani
essenti patent expir multipl gener launchedcelebrex eu lc ex fx celebrex expir develop emerg coxibcoxib essenti franchiseflector nsaid topic patch acut inflammatori hemostat post-surg wound gener competit pain essenti gener launch june eu lc ex fx aromasin develop emerg breast cancer breast cancer adjuv therapi colorect tumor devel pat exp europ cancer solid tumor gener competit foreigntot essenti cowen
compani data cowen compani
essenti expir eu lc ex fx xalatan develop emerg glaucoma xalcom edema degener ex right ositot essenti eu lc ex fx premarin develop emerg world-wide dose supportsmedrol eu lc ex fx medrol develop emerg estrogen launch eu japan ibd market rheumatoid arthriti en tab supportdepo expir tough agent type ii diabet combo-therapyglucotrol formul offset gener eros xl patent exp franchis declin partli off-set intern growthoth essenti cowen
compani data cowen compani
essenti drugsviagra launch ciali gener includ canada move eh eu lc ex fx viagra expir develop emerg treatment meddetrol la/detrol launch la/detrol eu lc ex fx detrol la/detrol la/detrol develop la/detrol emerg la/detrol bladderrevatio expir revatio eu lc ex fx revatio launch develop emerg essenti cowen
compani data cowen compani
essenti inject inject eu lc ex fx specialti inject inject develop inject emerg em repres signific growth opportunitiesspecialti inject siinfus system system eu lc ex fx infus system system develop system emerg system cash icu share close biosimilar remicad epogen approv herceptin piii avastin humira rituxan biosimilar eu lc ex fx biosimilar biosimilar epogen remicad herceptin approvedbiosimilar develop emerg eu lc ex fx develop emerg multi-specialti specialti api essenti essenti total sale total cowen
valuat methodolog primarili base current year forward price-to-earnings multipl
also consid total return/p ratio market cap/fre cash flow metric
failur pipelin product intellectu properti challeng econom sensit
price pressur and/or weaken consum demand develop market econom
and/or polit uncertainti emerg market chang tax law outlook
dividend fluctuat foreign exchang rate
risk includ success pipelin product patent expir greater
expect impact ep success streamlin and/or separ busi
structur outcom potenti
